Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
81,149,970
-
Number of holders
-
27
-
Total 13F shares, excl. options
-
3,257,983
-
Shares change
-
+3,257,983
-
Total reported value, excl. options
-
$39,909,852
-
Value change
-
+$39,909,852
-
Put/Call ratio
-
7.1%
-
Number of buys
-
27
-
Price
-
$12.25
Significant Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) as of Q3 2023
29 filings reported holding SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value as of Q3 2023.
Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) has 27 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,257,983 shares
of 81,149,970 outstanding shares and own 4% of the company stock.
Largest 10 shareholders include Driehaus Capital Management LLC (800,853 shares), Fairmount Funds Management LLC (378,421 shares), Polar Capital Holdings Plc (300,000 shares), WELLINGTON MANAGEMENT GROUP LLP (299,929 shares), Affinity Asset Advisors, LLC (242,297 shares), Logos Global Management LP (210,000 shares), EcoR1 Capital, LLC (199,996 shares), SUVRETTA CAPITAL MANAGEMENT, LLC (162,395 shares), Rock Springs Capital Management LP (136,556 shares), and COMMODORE CAPITAL LP (116,324 shares).
This table shows the top 27 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.